Please Wait...

Reproducibility of a Semi-automatic Knee Joint Analysis Tool

*Yu HJ, *Zhang Y, *Morges S, *Dawson E, *Galante N, *Belaroussi B, **Hoover KB, *Miller CG.

*BioClinica, Inc., Newtown, PA 18940
**Department of Radiology, VCU Medical Center, Richmond, PA 23219

BACKGROUND: Minimal Joint Space Width (mJSW, defined as the narrowest point of the tibio-femoral joint), and Anatomical Axis Angle (AAA, the angle formed by the lines bisecting the femur and the tibia as they intersect at the center of the tibial spine tips on plain radiographs of the knee can be used to evaluate the severity and progression of knee osteoarthritis  These measurements are therefore useful in determining subject eligibility and safety in clinical trials for osteoarthritis treatment.  To be practical for clinical trials, an efficient, accurate and precise measurement system is required which also features the QC tool for Inter-margin-distance (IMD).
OBJECTIVE: To evaluate a new semi-automated knee joint analysis tool to measure mJSW, AAA and IMD for use in clinical trials.

METHODS: Both mJSW and AAA were automatically calculated with minimal user interactions (Figure 1 and 2), while IMD was measured using a built-in caliper. Both mJSW and AAA were measured on AP knee radiographs from 30 subjects, by two experienced users, to assess inter- and intra-observer reproducibility. The Mean (and SD) value of absolute difference in each measurement was computed. IMD precision was not evaluated in this study. The 30 radiographs were obtained from a previous OA trial and had a range of KL scores from 0 to 4.

RESULTS: Table 1 and 2 show both the intra- and inter-observer intraclass correlation coefficient (ICC) values as well as repeatability coefficients (RCs) for medial mJSW, lateral mJSW, and AAA.

mJSW

The intra-observer reproducibility of mJSW ranged from 0.95 to 0.99 for ICC and 0.36 to 0.64 mm for RC. The inter-observer reproducibility of mJSW ranged from 0.85 to 0.98 for ICC and 0.59 to 1.33 mm for RC.

AAA

The intra-observer ICC of AAA were 0.95 and 0.97 for observer A and B, respectively. The inter-observer ICC of AAA were 0.85 and 0.92 for session 1 and 2, respectively. The RCs ranged from 1.54o to 3.04o.

CONCLUSION: The analysis tool presented here provided good intra- and inter-observer reproducibility.  The constraints aided in the user a rapid identification of location and reproducible landmarks.  This comprehensive semi-automated analysis tool and is suitable for the assessment of knee joints in clinical trials.

SPONSOR: BioClinica Inc.

DICLOSURE STATEMENT: None

ACKNOWLEDGMENT: None

CORRESPONDENCE ADDRESS: colin.miller@bioclinica.com

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

ASCPT 2018 Annual Meeting https://t.co/i0mjYbBq5N Join @Bioclinica Research's Open House 3/22 https://t.co/citlLotbD7
bioclinica (2 days ago)
Heading to DC for DIA's #Pharmacovigilance & Risk Mgmt Strategies Conf.? Visit @Bioclinica in booth 32. Preview our… https://t.co/alU1sCg04l
bioclinica (2 days ago)
Kevin Bishop, named a 'Top Innovator' in #clinicaltrials by @CenterWatch See how we're reducing risk to the clinic… https://t.co/rXBGvIh9Wr
bioclinica (3 days ago)
RT @CenterWatch: Congratulations to all our #2018TopInovators! Read about the innovations in the #CWMonthly special edition, https://t.co/Y…
bioclinica (2 weeks ago)
RT @CenterWatch: .@Pfizer demonstrates leadership in #clinicaltrial innovation with two spots on the @CenterWatch #2018TopInnovators, https…
bioclinica (2 weeks ago)
RT @jheanne: I just contributed towards 'Joby' on https://t.co/EHt69JFLZ9 Best wishes to Joby and all our @Bioclinica team members! @Oxfam…
bioclinica (2 weeks ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen